Chemical pleurodesis for the management of refractory hepatic hydrothorax in patients with decompensated liver cirrhosis

다국어 초록 (Multilingual Abstract)

Background/Aims: Hepatic hydrothorax in patients with decompensated liver cirrhosis is a challenging problem.
Treatment with diuretics and intermittent thoracentesis can be effective in selected patients. However, there are few effective therapeutic options in patients who are intolerant of these therapies. This study investigated the clinical usefulness of chemical pleurodesis with or without video-assisted thoracoscopic surgery (VATS) for patients with refractory hepatic hydrothorax. Methods: Eleven consecutive patients with refractory hepatic hydrothorax who underwent chemical pleurodesis with or without VATS between July 2007 and February 2011 were enrolled in this study. The medical records and radiologic imagings of these patients were thoroughly reviewed. Results: The median number of chemical pleurodesis sessions performed was 3 (range: 2-10). Successful pleurodesis was achieved in 8 of the 11 patients (72.7%),5 (62.5%) of whom remained asymptomatic and hydrothorax free for a median follow-up of 16 weeks (range: 2-52 weeks).
Complications were low-grade fever/leukocytosis (n=11, 100%), pneumonia (n=1, 9.1%), pneumothorax (n=4, 36.4%),azotemia/acute renal failure (n=6, 54.6%), and hepatic encephalopathy (n=4, 36.4%). Five patients were suspected as having procedure-related mortality (45.5%) due to the occurrence of acute renal failure with hepatic failure. The overall survival was significantly longer in the success group than in the non-success group. Conclusions: Although chemical pleurodesis may improve the clinical symptoms and the radiologic findings in as many as 72.7% of patients with refractory hepatic hydrothorax, a significantly high prevalence of procedure-related morbidity and mortality hinders the routine application of this procedure for such patients.

참고문헌 (Reference)

1 Ferrante D, "Video-assisted thoracoscopic surgery with talc pleurodesis in the management of symptomatic hepatic hydrothorax" 97 : 3172-3175, 2002

2 Saito R, "Two cases of intractable hepatic hydrothorax successfully treated with nasal CPAP" 103 : 1146-1151, 2006

3 Andrade RJ, "Transjugular intrahepatic portosystemic shunt for the management of hepatic hydrothorax in the absence of ascites" 22 : 305-307, 1996

4 Chalasani N, "Transjugular intrahepatic portosystemic shunt (Trends Pharmacal Sci) for refractory hepatic hydrothorax: good for the lungs, not so good for the liver" 26 : 286-, 1997

5 Strauss RM, "Transjugular intrahepatic portal systemic shunt for the management of symptomatic cirrhotic hydrothorax" 89 : 1520-1522, 1994

6 Gordon FD, "The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt" 25 : 1366-1369, 1997

7 Ikard RW, "Persistent hepatic hydrothorax after peritoneojugular shunt" 115 : 1125-1127, 1980

8 Massard G, "Minimally invasive management for first and recurrent pneumothorax" 66 : 592-599, 1998

9 Mouroux J, "Management of pleural effusion of cirrhotic origin" 109 : 1093-1096, 1996

10 Alberts WM, "Hepatic hydrothorax. Cause and management" 151 : 2383-2388, 1991

11 Runyon BA, "Hepatic hydrothorax is a relative contraindication to chest tube insertion" 81 : 566-567, 1986

12 Rubinstein D, "Hepatic hydrothorax in the absence of clinical ascites: diagnosis and management" 88 : 188-191, 1985

13 Xiol X, "Hepatic hydrothorax" 4 : 239-242, 1998

14 Strauss RM, "Hepatic hydrothorax" 17 : 227-232, 1997

15 Morrow CS, "Hepatic hydrothorax" 49 : 193-203, 1958

16 Arroyo V, "Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club" 23 : 164-176, 1996